Modality
mRNA
MOA
BETi
Target
WEE1
Pathway
Angiogenesis
HCCPBC
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
Mar 2020
→ Nov 2030
Phase 2Current
NCT04441573
2,646 pts·HCC
2020-03→2030-11·Completed
2,646 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-014.6y awayPh3 Readout· HCC
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Complet…
Catalysts
Ph3 Readout
2030-11-01 · 4.6y away
HCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04441573 | Phase 2/3 | HCC | Completed | 2646 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |